Jonathan Kimmelman (Jonathan Kimmleman)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 45

Top Topics

Infectious Diseases

Top Venues

Clinical trials (London, England)

Annals of internal medicine

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Jonathan Kimmelman
Commentary on Astrachan et al. The transmutation of research risk in pragmatic clinical trials. Clinical trials (London, England) (2024)
Hannah Moyer, Robyn Mellett, Karine Vigneault, Maya McKeown, Jason Karlawish, Erika Augustine, Lon Schneider, Jonathan Kimmelman
Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development. Neurology 103 (1) (2024)
Peter Grabitz, Lana Saksone, Susanne Gabriele Schorr, Johannes Schwietering, Merlin Bittlinger, Jonathan Kimmelman
Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis. Clinical trials (London, England) 21 (4) (2024)
Hannah Moyer, Robyn Mellett, Karine Vigneault, Maya McKeown, Jason Karlawish, Erika Augustine, Lon Schneider, Jonathan Kimmelman
Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development. Neurology 103 (1) (2024)
Hannah Moyer, Robyn Mellett, Karine Vigneault, Maya McKeown, Jason Karlawish, Erika Augustine, Lon Schneider, Jonathan Kimmelman
Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development. Neurology 103 (1) (2024)
Hannah Moyer, Robyn Mellett, Karine Vigneault, Maya McKeown, Jason Karlawish, Erika Augustine, Lon Schneider, Jonathan Kimmelman
Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development. Neurology 103 (1) (2024)
Renata Iskander, Hannah Moyer, Dean A Fergusson, Sean McGrath, Andrea Benedetti, Jonathan Kimmelman
The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis. Annals of internal medicine (2024)
Renata Iskander, Hannah Moyer, Dean A Fergusson, Sean McGrath, Andrea Benedetti, Jonathan Kimmelman
The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis. Annals of internal medicine 177 (6) (2024)
Peter Grabitz, Lana Saksone, Susanne Gabriele Schorr, Johannes Schwietering, Merlin Bittlinger, Jonathan Kimmelman
Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis. Clinical trials (London, England) (2024)
Renata Iskander, Hannah Moyer, Dean A Fergusson, Sean McGrath, Andrea Benedetti, Jonathan Kimmelman
The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis. Annals of internal medicine 177 (6) (2024)
Adélaïde Doussau, Patrick Kane, Jeffrey Peppercorn, Aden C Feustel, Sylviya Ganeshamoorthy, Natasha Kekre, Daniel M Benjamin, Jonathan Kimmelman
The impact of feedback training on prediction of cancer clinical trial results. Clinical trials (London, England) (2023)
Nora Hutchinson, Selin Bicer, Emma Feldhake, Benjamin Gregory Carlisle, Mithat Gönen, Joseph C Del Paggio, Jonathan Kimmelman
Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies. JCO oncology practice 20 (2) (2023)
Nora Hutchinson, Selin Bicer, Emma Feldhake, Benjamin Gregory Carlisle, Mithat Gönen, Joseph C Del Paggio, Jonathan Kimmelman
Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies. JCO oncology practice 20 (2) (2023)
Nora Hutchinson, Selin Bicer, Emma Feldhake, Benjamin Gregory Carlisle, Mithat Gönen, Joseph C Del Paggio, Jonathan Kimmelman
Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies. JCO oncology practice (2023)
Merlin Bittlinger, Selin Bicer, Jeffrey M Peppercorn, Jonathan Kimmelman
Ethical Considerations for Phase I Trials in Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (30) (2022)
Charlotte Ouimet, Gauthier Bouche, Jonathan Kimmelman
Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study. PloS one 17 (9) (2022)
Fareed A Awan, Andrew B Becker, Yuetong Wang, Jonathan Kimmelman
Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis. Annals of internal medicine (2022)
Daniel M Benjamin, Spencer P Hey, Amanda MacPherson, Yasmina Hachem, Kara S Smith, Sean X Zhang, Sandy Wong, Samantha Dolter, David R Mandel, Jonathan Kimmelman
Principal investigators over-optimistically forecast scientific and operational outcomes for clinical trials. PloS one 17 (2) (2022)
Patrick Bodilly Kane, Hannah Moyer, Amanda MacPherson, Jesse Papenburg, Brian J Ward, Stephen B Broomell, Jonathan Kimmelman
Relationship between lay and expert perceptions of COVID-19 vaccine development timelines in Canada and USA. PloS one 17 (2) (2022)
Nora Hutchinson, Hannah Moyer, Deborah A Zarin, Jonathan Kimmelman
The proportion of randomized controlled trials that inform clinical practice. eLife 11 (2022)
Scott Yung Ho Kim, Jonathan Kimmelman
Practical steps to identifying the research risk of pragmatic trials. Clinical trials (London, England) 19 (2) (2022)
Erica Wennberg, Sarah B Windle, Kristian B Filion, Genevieve Gore, Brett D Thombs, Irina Kudrina, Elena Paraskevopoulos, Marc O Martel, Jonathan Kimmelman, Sonia Johnson, Andrew Taylor, Mark J Eisenberg
Interventions for physician prescribers of opioids for chronic non-cancer pain: protocol for an overview of systematic reviews. BMJ open 12 (3) (2022)
Elisabeth Oliviero, Georgiana Kourkopoulos, Jonathan Kimmelman
Success rates for US and Canadian anticancer drug development efforts in pediatric oncology. Pediatric blood & cancer 69 (8) (2022)
Patrick Bodilly Kane, Merlin Bittlinger, Jonathan Kimmelman
Individualized therapy trials: navigating patient care, research goals and ethics. Nature medicine 27 (10) (2021)
Jonathan Kimmelman
Clinical Trials to authors: Please pre-register your studies! Clinical trials (London, England) 18 (6) (2021)
Patrick Bodilly Kane, Jonathan Kimmelman
Is preclinical research in cancer biology reproducible enough? eLife 10 (2021)
Amanda MacPherson, Nora Hutchinson, Oliver Schneider, Elisabeth Oliviero, Emma Feldhake, Charlotte Ouimet, Jacky Sheng, Fareed A Awan, Catherine Wang, Jesse Papenburg, Nicole E Basta, Jonathan Kimmelman
Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases. Annals of internal medicine 174 (3) (2020)
Michael Yu, Thomas C Darton, Jonathan Kimmelman
Decision analysis approach to risk/benefit evaluation in the ethical review of controlled human infection studies. Bioethics 34 (8) (2020)
Jonathan Kimmelman
Commentary on Kahrass et al: The sublime inertia of informed consent language in early phase clinical trials involving patients. Clinical trials (London, England) 18 (1) (2020)
Benjamin Gregory Carlisle, Tiger Zheng, Jonathan Kimmelman
Imatinib and the long tail of targeted drug development. Nature reviews. Clinical oncology 17 (1) (2020)
Jonathan Kimmelman
Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nature reviews. Clinical oncology 16 (12) (2020)
Daniel M Benjamin, David R Mandel, Tristan Barnes, Monika K Krzyzanowska, Natasha Leighl, Ian F Tannock, Jonathan Kimmelman
Can Oncologists Predict the Efficacy of Treatments in Randomized Trials? The oncologist 26 (1) (2020)
Patrick Bodilly Kane, Scott Y H Kim, Jonathan Kimmelman
What Research Ethics (Often) Gets Wrong about Minimal Risk. The American journal of bioethics : AJOB 20 (1) (2020)
Eli Gumnit, Aden C Feustel, Sandy Wong, Rafia Bosan, Nora Hutchinson, Jonathan Kimmelman
The proportion of North American cancer trials that evaluate novel targets. Investigational new drugs 39 (1) (2020)
Pavel Atanasov, Andreas Diamantaras, Amanda MacPherson, Esther Vinarov, Daniel M Benjamin, Ian Shrier, Friedemann Paul, Ulrich Dirnagl, Jonathan Kimmelman
Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. Neurology 95 (5) (2020)
Jonathan Kimmelman
Why IRBs should protect bystanders in human research. Bioethics 34 (9) (2020)
Jonathan Kimmelman
Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. Nature reviews. Clinical oncology 17 (2) (2020)
Jonathan Kimmelman
Organ donor intervention trials and the ethical challenge of bystander organ recipients. Clinical trials (London, England) 16 (5) (2019)
Benjamin Gregory Carlisle, Adelaide Doussau, Jonathan Kimmelman
Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical trials (London, England) 17 (1) (2019)
Adelaide Doussau, Esther Vinarov, Brianna Barsanti-Innes, Jonathan Kimmelman
Comparison between protocols and publications for prognostic and predictive cancer biomarker studies. Clinical trials (London, England) 17 (1) (2019)
Lauren A Richardson, Sandra L Schmid, Avinash Bhandoola, Christelle Harly, Anders Hedenström, Michael T Laub, Georgina M Mace, Piali Sengupta, Ann M Stock, Andrew F Read, Harmit Singh Malik, Mark Estelle, Sally Lowell, Jonathan Kimmelman
The PLOS Biology XV Collection: 15 Years of Exceptional Science Highlighted across 12 Months. PLoS biology 17 (2) (2019)
Nir Eyal, Jonathan Kimmelman, Lisa G Holtzman, Marc Lipsitch
Regulating impact on bystanders in clinical trials: An unsettled frontier. Clinical trials (London, England) 16 (5) (2019)
Michael Pratte, Sylviya Ganeshamoorthy, Benjamin Carlisle, Jonathan Kimmelman
How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence? International journal of cancer 145 (12) (2019)
Aden C Feustel, Amanda MacPherson, Dean A Fergusson, Karl Kieburtz, Jonathan Kimmelman
Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology 94 (1) (2019)
James Mattina, Benjamin Carlisle, Yasmina Hachem, Dean Fergusson, Jonathan Kimmelman
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS biology 15 (2) (2017)